ArticleDiscover oncology2026
Exploring molecular mechanisms of radioactive iodine therapy in thyroid cancer using single-cell RNA sequencing data.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate the role of ubiquitination-related differentially expressed genes (URDEGs) in thyroid carcinoma (THCA) and their implications for predicting responses to radioactive iodine (RAI) therapy.
methodsWe analyzed data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases using TCGA biolinks and GEO query tools for data acquisition and normalization. Differential expression analysis was performed with DESeq2 to identify URDEGs between RAI-sensitive and RAI- refractory groups. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted using ClusterProfiler. A prognostic risk model was built using Cox regression and Least Absolute Shrinkage and Selection Operator (LASSO) regression. Single-cell RNA sequencing data were analyzed with Seurat for clustering and annotation. Gene Set Variation Analysis (GSVA) was used to assess pathway enrichment across various cell subpopulations.
resultsA total of 25 URDEGs were identified, which were enriched in processes related to cytoskeleton organization and pathways including the peroxisome proliferator-activated receptor (PPAR) signaling pathway. A prognostic model based on four URDEGs—INSM2, TAGLN3, MDGA2, and SIK1—demonstrated strong predictive capability. Immune infiltration analysis revealed significant differences in immune cell composition between high- and low-risk groups. Single-cell analysis identified 74,497 cells across 22 clusters and nine cell types, revealing gene expression patterns that highlight cellular heterogeneity.
conclusionURDEGs show potential as biomarkers for predicting RAI therapy response and prognosis in THCA. These findings provide insights for personalized therapeutic strategies targeting specific molecular pathways in THCA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.